Epilepsy Market Regional Analysis:
North American Market Insights
North America region is poised to dominate around 39.5% market share by 2035. The growth of the market can be attributed to the increasing prevalence and estimated over 1.2% of the total US population had active epilepsy. Further, the presence of a strong healthcare network along with the availability of supportive policies by the regulatory bodies that promote the market players to opt for easy testing of epilepsy drugs over a large target population. In addition, the region's expanding healthcare industry and rising healthcare expenditure are also anticipated to boost market growth.
APAC Market Insights
The Asia Pacific epilepsy market is also projected to grow at a significant pace with a notable CAGR rate. The growth of the market in the region can be attributed to similar factors, such as rising cases of neurological diseases and a growing geriatric population with various types of brain disorders. Also, the rapid growth of the healthcare industry and rising investment in enhancing the healthcare system are other factors that are anticipated to create a positive outlook for generating significant revenue. Moreover, the presence of a large pool of patients and the rapid escalation of non-communicable diseases are also expected to create a positive outlook .
